Galectin Therapeutics, Inc. (GALT) Reaches $3.28 After 9.00% Down Move; 7 Bullish Analysts Covering Tate & Lyle plc (LON:TATE)

May 10, 2018 - By Moses P. Lee

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) is a huge mover today! The stock decreased 3.53% or $0.12 during the last trading session, reaching $3.28. About 101,641 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.90% since May 10, 2017 and is uptrending. It has outperformed by 66.35% the S&P500.The move comes after 7 months negative chart setup for the $123.23M company. It was reported on May, 10 by Barchart.com. We have $2.98 PT which if reached, will make NASDAQ:GALT worth $11.09M less.

Among 19 analysts covering Tate Lyle PLC (LON:TATE), 7 have Buy rating, 0 Sell and 12 Hold. Therefore 37% are positive. Tate Lyle PLC had 217 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Tate & Lyle plc (LON:TATE) has “Hold” rating given on Monday, May 15 by Berenberg. Goldman Sachs maintained Tate & Lyle plc (LON:TATE) rating on Thursday, November 26. Goldman Sachs has “Neutral” rating and GBX 615 target. Liberum Capital maintained the stock with “Buy” rating in Tuesday, January 17 report. The rating was maintained by Societe Generale on Friday, May 27 with “Buy”. Liberum Capital maintained it with “Buy” rating and GBX 850 target in Monday, March 5 report. The rating was maintained by Jefferies with “Buy” on Tuesday, February 7. The rating was maintained by Liberum Capital on Monday, November 14 with “Buy”. Liberum Capital maintained it with “Buy” rating and GBX 850 target in Friday, January 19 report. On Monday, October 12 the stock rating was maintained by Credit Suisse with “Neutral”. The stock of Tate & Lyle plc (LON:TATE) has “Buy” rating given on Thursday, October 8 by Jefferies. See Tate & Lyle plc (LON:TATE) latest ratings:

17/04/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 850.00 New Target: GBX 850.00 Maintain
17/04/2018 Broker: Shore Capital Rating: Hold New Target: GBX 554.00 Maintain
05/04/2018 Broker: BNP Paribas Rating: Neutral Old Target: GBX 670.00 New Target: GBX 660.00 Maintain
23/03/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 850.00 New Target: GBX 850.00 Maintain
15/03/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 850.00 New Target: GBX 850.00 Maintain
05/03/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 850.00 New Target: GBX 850.00 Maintain
13/02/2018 Broker: Kepler Cheuvreux Rating: Buy Old Target: GBX 630.00 New Target: GBX 630.00 Upgrade
12/02/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 725.00 New Target: GBX 650.00 Maintain
08/02/2018 Broker: Credit Agricole Rating: Neutral Old Target: GBX 710.00 New Target: GBX 670.00 Reiteration
08/02/2018 Broker: Kepler Cheuvreux Rating: Hold Old Target: GBX 690.00 New Target: GBX 660.00 Maintain

Investors sentiment decreased to 0.53 in Q4 2017. Its down 0.14, from 0.67 in 2017Q3. It dived, as 6 investors sold Galectin Therapeutics, Inc. shares while 13 reduced holdings. 7 funds opened positions while 3 raised stakes. 3.08 million shares or 4.50% less from 3.22 million shares in 2017Q3 were reported. Goldman Sachs Gp Inc accumulated 12,528 shares. Riggs Asset Managment reported 1,000 shares. Neuberger Berman Grp Ltd Liability Corporation reported 82,494 shares. Dynamic Advsr Solutions Ltd accumulated 10,000 shares. Wells Fargo & Mn holds 0% or 10,882 shares in its portfolio. Susquehanna International Grp Llp invested in 69,975 shares. Cetera Advisor Ntwk Ltd Com owns 15,721 shares or 0% of their US portfolio. Bankshares Of America De stated it has 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Norris Perne French Llp Mi invested in 0.01% or 30,500 shares. California Employees Retirement System invested in 0% or 23,450 shares. Art Ltd Liability Com holds 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 36,071 shares. Schwab Charles Invest owns 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 21,400 shares. Buckingham Asset Mgmt Ltd owns 10,000 shares. Us Savings Bank De holds 118,921 shares or 0% of its portfolio. Comml Bank Of Ny Mellon Corporation owns 19,930 shares for 0% of their portfolio.

Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on May, 21. They expect $-0.13 EPS, up 13.33% or $0.02 from last year’s $-0.15 per share. After $-0.07 actual EPS reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 85.71% negative EPS growth.

More recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Nasdaq.com which released: “Recent Analysis Shows Alphabet, Northrop Grumman, HomeStreet, Galectin Therapeutics, AZZ, and Restoration …” on April 26, 2018. Also Globenewswire.com published the news titled: “Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018” on April 18, 2018. Seekingalpha.com‘s news article titled: “Key events next week – healthcare” with publication date: April 20, 2018 was also an interesting one.

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics has $8 highest and $0.75 lowest target. $4.63’s average target is 41.16% above currents $3.28 stock price. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) has “Buy” rating given on Monday, March 28 by H.C. Wainwright. The rating was downgraded by TH Capital on Wednesday, September 28 to “Sell”. H.C. Wainwright downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Thursday, September 29. H.C. Wainwright has “Neutral” rating and $1.50 target. The stock has “Buy” rating by H.C. Wainwright on Monday, September 21. Roth Capital maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Thursday, January 4. Roth Capital has “Buy” rating and $8.0 target. H.C. Wainwright maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) on Wednesday, June 14 with “Buy” rating. The firm earned “Sell” rating on Wednesday, September 28 by Roth Capital. FBR Capital downgraded it to “Mkt Perform” rating and $2 target in Monday, October 3 report. Roth Capital maintained it with “Buy” rating and $3.0 target in Thursday, December 7 report. H.C. Wainwright upgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) on Thursday, March 30 to “Buy” rating.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $123.23 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Since January 25, 2018, it had 2 insider buys, and 4 insider sales for $2.67 million activity. 244,444 shares were sold by CZIRR JAMES C, worth $1.33M. The insider 10X Fund – L.P. sold 244,444 shares worth $1.33 million. 4,000 shares were sold by ZUCCONI THEODORE DANIEL, worth $14,320 on Monday, April 16. $8,191 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was bought by FREEMAN KEVIN D. $16,745 worth of stock was sold by CALLICUTT JACK W on Wednesday, April 4.

Tate & Lyle PLC, together with its subsidiaries, provides ingredients and solutions to the food, beverage, and other industries in the United States, the United Kingdom, other European countries, and internationally. The company has market cap of 2.79 billion GBP. It operates through two divisions, Speciality Food Ingredients and Bulk Ingredients. It has a 11.27 P/E ratio. The firm offers texturants, including corn starches, clean-label starches, and stabilizer systems; sweeteners, such as high intensity sweeteners and specialty sweeteners; and health and wellness ingredients comprising dietary fibers and oat proteins.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Moses P. Lee

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: